(Q36890177)

English

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

scientific article published on September 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience (English)

1 reference

Europe PubMed Central

16 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ana Maria Gonzalez-Angulo

2

object named as

Ana M Gonzalez-Angulo

1 reference

Europe PubMed Central

16 August 2017

Gabriel N Hortobagyi

8

object named as

Gabriel N Hortobagyi

1 reference

Europe PubMed Central

16 August 2017

9

object named as

Aman U Buzdar

1 reference

Europe PubMed Central

16 August 2017

author name string

Shaheenah Dawood

1

1 reference

Europe PubMed Central

16 August 2017

Florentia Peintinger

3

1 reference

Europe PubMed Central

16 August 2017

Kristine Broglio

4

1 reference

Europe PubMed Central

16 August 2017

William F Symmans

5

1 reference

Europe PubMed Central

16 August 2017

Shu-Wan Kau

6

1 reference

Europe PubMed Central

16 August 2017

Rabiul Islam

7

1 reference

Europe PubMed Central

16 August 2017

language of work or name

0 references

publication date

1 September 2007

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

110

1 reference

Europe PubMed Central

16 August 2017

1195-1200

1 reference

Europe PubMed Central

16 August 2017

6

1 reference

Europe PubMed Central

16 August 2017

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22895

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22895

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36890177&oldid=2121328695"